Drug - International Biopharmaceutical Industry

news

Biogen’s Alzheimer’s drug sales remain slow as company warns of further cost cuts

Biogen recorded $1 million in revenue from its new treatment for Alzheimer's disease in the last quarter of 2021, offering the latest evidence that the drug, which ca...

6 February 2022 news Alzheimer | Biogen

Continue Reading →

news

Lilly slows FDA submission of Alzheimer’s drug after Medicare decision

Dive Brief: Eli Lilly is pushing back the timing for when it expects to finish submitting an application for U.S. approval of its experimental drug for Alzheimer's...

6 February 2022 news Alzheimer | Drug

Continue Reading →

news

A biotech wins the first FDA drug approval in a rare type of eye cancer

Dive Brief: The Food and Drug Administration on Tuesday granted approval to the first drug for a rare cancer of the eye that has spread elsewhere or grown too larg...

27 January 2022 news Biotech | cancer

Continue Reading →

news

Incyte withdraws cancer drug from FDA review after discussions with regulator

Dive Brief: Incyte is pulling its application for an experimental lymphoma medicine after determining that the Food and Drug Administration's requirements for conf...

27 January 2022 news cancer | Drug

Continue Reading →

news

Cortexyme to shift focus after FDA places hold on experimental Alzheimer’s drug

Dive Brief: The Food and Drug Administration has ordered California biotech Cortexyme to stop testing of an experimental Alzheimer's disease drug, notifying the dr...

27 January 2022 news Alzheimer | Biotech

Continue Reading →

news

EQRx builds case for cancer drug it hopes can disrupt market

Dive Brief: EQRx, which aims to bring new medicines to market at "radically lower" prices, said the experimental lung cancer drug it co-owns with Chinese biotech C...

20 January 2022 news cancer | Drug

Continue Reading →

news

Pfizer’s big bet on mRNA, Biogen ‘proven wrong’ on Aduhelm price and the next cell therapies

Biotechnology stocks ended the first day of the J.P. Morgan Healthcare Conference in the green, but only barely. By Monday afternoon, a closely followed index of the ...

14 January 2022 news Alzheimer | cell

Continue Reading →

news

FDA panel turns down Reata kidney disease drug in unanimous vote

The company's shares plummeted by more than 40% in early Thursday trading after taking a hit earlier in the week when the FDA released the documents that outlined its...

10 December 2021 news Alport syndrome | Drug

Continue Reading →

news

Cortexyme plans path forward for Alzheimer’s drug that failed study

Faced with the failure of a key clinical trial, a California-based biotech is pressing ahead with plans to test its experimental Alzheimer's drug in another study, co...

15 November 2021 news Alzheimer | Cortexyme

Continue Reading →

news

Novartis hits another setback in plan to repurpose rare disease drug in lung cancer

Novartis' testing of canakinumab, which works by curbing inflammatory signaling in cells, for the seemingly unrelated use in lung cancer stems from an intriguing 2011...

29 October 2021 news cancer | cells

Continue Reading →